おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
MicuRx Pharmaceuticals
company
About
MicuRx discovers and develops novel antimicrobials to treat drug-resistant infections and other diseases of significant unmet medical need
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $55M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2007
- Number Of Employee
- 101 - 250
- Operating Status
- Active
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$55M ¥1B
MicuRx Pharmaceuticals has raised a total of
$55M ¥1B
in funding over 2 rounds. Their latest funding was raised on
Dec 21, 2020 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 21, 2020 | Series E | ¥700M | 1 | — | — | Detail |
| Aug 5, 2020 | Series D | ¥300M | 1 | — | — | Detail |
| Sep 26, 2016 | Series C | $55M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
MicuRx Pharmaceuticals is funded by 3 investors.
Zhongtai Venture Capital
and Sinopharm-CICC
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series E |
|
|
— | Series D |
|
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
